Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.41 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | BAD | Q92934 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487798 | 1.00 | SRC (0.49) | SRCADORA2AADORA1SLC13A5CHRNE | |
| SCHEMBL10152492 | 0.89 | SRC (0.37) | SRCADORA2AADORA1SLC13A5CHRNE | |
| SCHEMBL9358469 | 0.82 | SRC (0.49) | SRCADORA2AADORA1SLC13A5REN | |
| SCHEMBL31310576 | 0.82 | SRC (0.49) | SRCADORA2AADORA1SLC13A5REN | |
| SCHEMBL5542208 | 0.81 | SRC (0.49) | SRCADORA2AADORA1SLC13A5REN | |
| SCHEMBL10911692 | 0.79 | SRC (0.43) | SRCADORA2AADORA1SLC13A5REN | |
| SCHEMBL21921081 | 0.78 | ADORA2A (0.44) | SRCADORA2AADORA1SLC13A5REN | |
| SCHEMBL5542213 | 0.78 | SRC (0.42) | SRCADORA2AADORA1SLC13A5REN | |
| SCHEMBL28690726 | 0.77 | IAPP (0.45) | SRCADORA2AADORA1SLC13A5F2 | |
| SCHEMBL13312019 | 0.76 | SRC (0.37) | SRCADORA2AADORA1SLC13A5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7070083-A | — | — | None | — | — | JP | disclosed |
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111032034-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3675848-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2022-03-23 | — | — | EP | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| WO-2017037116-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037116-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-09 | — | — | WO | disclosed |
| US-5523317-A | ADMINISTERING IMIDAZOLE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 1996-06-04 | — | — | US | disclosed |
| JP-H0770083-A | ANTIHYPERTENSIVE AGENT CONTAINING IMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | NIPPON CHEMIPHAR CO LTD | 1995-03-14 | — | — | JP | disclosed |
| EP-0633026-A1 | Use of imidazole derivative for antihypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0239129-B1 | HYDROQUINOLINE COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-4963566-A | ANTIULCER AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
| US-4729998-A | Cyclic carbamates and fungicidal use | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1988-03-08 | — | — | US | disclosed |
| EP-0239927-A1 | Cyclic carbamates | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1987-10-07 | — | — | EP | disclosed |
| EP-0239129-A2 | Hydroquinoline compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, VKORC1L1 | SRC 3670/4885ADORA2A 2377/4885ADORA1 3010/4885 |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | SRC 3859/4885ADORA2A 2072/4885ADORA1 3325/4885 |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | SRC 1840/4885ADORA2A 1820/4885ADORA1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.